Turkey ADHD Therapeutics Market Report 2022 to 2030

Turkey ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

$ 3999

Turkey's Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market is projected to grow from $236 Mn in 2022 to $438 Mn in 2030 with a CAGR of 8% for the year 2022-2030. The rising incidence and awareness of ADHD in the Turkish population as well as the introduction of better diagnostic tools are the major growth drivers for the market. The Turkey ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Some of the major competitors in the market are İmuneks Farma, Turgut İlaç, and Mallinckrodt.

ID: IN10TRPH028 CATEGORY: Pharmaceuticals GEOGRAPHY: Turkey AUTHOR: Parul Choudhary

Buy Now

Turkey Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Executive Analysis

The Turkey Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $236 Mn in 2022 and is projected to reach $438 Mn in 2030, exhibiting a CAGR of 8% during the forecast period. According to the Turkish government's 2022 budget proposal, the health industry will receive funding totaling $35 Bn, an increase of about 18% from the previous year. This budgetary allotment will be used to finance a variety of healthcare projects and programs, such as the delivery of medical services and treatments, the acquisition of medical tools and supplies, and the development and renovation of healthcare facilities across the nation.

In Turkey, 12.4% of children with disability and 19.5% of children without impairment have ADHD. According to a recent study by the Turkish Association for Child and Adolescent Psychiatry, more children than the average number of children worldwide in Turkey have attention deficit hyperactivity disorder (ADHD), which affects one in ten of them. Children with ADHD experience a loss of functioning, which has a negative effect on their social and scholastic lives. In addition to causing delays in social and academic development, ADHD increases children's risk of accidents and injuries for a number of reasons, particularly because of their impulsivity and inattentiveness. Along with difficulties paying attention, impulsivity, risky behaviors, problems with motor coordination, and difficulties with executive functions also increase the risk of accidents in children and teenagers with ADHD. When ADHD and Oppositional Defiant Disorder (ODD) coexist, the chance of injury is increased.

A selective norepinephrine (NE) reuptake inhibitor called atomoxetine has been authorized for the treatment of attention deficit hyperactivity disorder in children, teenagers, and adults in Turkey. The presynaptic norepinephrine transporter (NET) is inhibited by atomoxetine, blocking the reuptake of NE in the entire brain as well as the reuptake of dopamine in particular brain regions, such as the prefrontal cortex (PFC). Numerous studies have been released that claim atomoxetine is successful in treating the symptoms of ADHD in kids who have a variety of comorbid conditions. In some circumstances, it's conceivable that atomoxetine will help reduce comorbidity symptoms. Atomoxetine has a very low risk of abuse or misuse and can be taken as a single daily dose or divided into two equally scheduled doses.

turkey attention deficit hyperactivity disorder therapeutics market analysis

Market Dynamics

Market Growth Drivers

In Turkey, there is a rising consciousness of ADHD, which is resulting in more precise diagnoses and treatments. Healthcare workers and advocacy organizations working to increase awareness of the disorder are the ones driving the growth of Turkey's ADHD therapeutics market. Adults and children in Turkey are being diagnosed with ADHD at an increasing rate. Better diagnostic tools and a greater understanding of the disorder among medical experts are responsible for this. In Turkey, there are now more choices for treating ADHD, including medication and behavioral therapy. As a result, more patients are able to obtain effective treatments, which is increasing the demand for these medications.

Market Restraints

In Turkey, including ADHD, there is still some stigma attached to mental health conditions. This might discourage some patients from getting care, which would restrain the Turkey ADHD therapeutics market's expansion. The availability of treatment options for patients is presently constrained by the small number of businesses that are active in Turkey's ADHD therapeutics market.

Competitive Landscape

Key Players

Lidssen Pharma (TUR)
Zeincro Turkey (TUR)
Kuzey Pharma (TUR)
İmuneks Farma (TUR)
Turgut İlaç (TUR)
Mallinckrodt
Amneal Pharmaceuticals
Noven Pharmaceuticals
Purdue Parma
Zhengda Fenghai

Healthcare Policies and Regulatory Landscape

The Turkish Medicines and Medical Devices Agency (TTCK - Türkiye laç ve Tbbi Cihaz Kurumu) is the governing body in charge of regulating drugs and medical equipment in Turkey. TTCK is a separate regulating organization that works for the Ministry of Health. TTCK is in charge of policing how prescription drugs, medical devices, and other healthcare goods are approved, registered, and monitored after they are put on the market in Turkey. This includes examining the results of clinical trials, checking out the factories, and keeping an eye on unfavorable outcomes. TTCK is in charge of both regulating duties and the promotion of public health in Turkey. This entails educating the public about the significance of using safe and efficient healthcare products as well as supplying healthcare workers with education and training.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Segmentation

By Drug Type (Revenue, USD Billion):

Stimulants
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Lisdexamfetamine
- Others
Non-Stimulants
- Atomoxetine
- Bupropion
- Guanfacine
- Clonidine

By Age Group (Revenue, USD Billion):

Pediatric And Adolescent
Adult

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Speciality Clinics
Retail Pharmacies
e-Commerce

By Psychotherapy (Revenue, USD Billion):

Behaviour Therapy
Cognitive Behavioral Therapy
Interpersonal Psychotherapy
Family Therapy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.